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We envision the use of human fetal bone cells for engineered regeneration of adult skeletal tissue. A description of their cellular function
is then necessary. To our knowledge, there is no description of human primary fetal bone cells treated with differentiation factors. The
characterization of fetal bone cells is particularly important as the pattern of secreted proteins from osteoblasts has been shown to change
during aging. In the first part of this work, human primary fetal bone cells were compared to adult bone cells and mesenchymal stem cells for
their ability to proliferate and to differentiate into osteoblasts in vitro. Cell proliferation, gene expression of bone markers, alkaline
phosphatase (ALP) activity, and mineralization were analyzed during a time-course study. In the second part of this paper, bone fetal cells
behavior exposed to osteogenic factors is further detailed. The doubling time of fetal bone cells was comparable to mesenchymal stem cells
but significantly shorter than for adult bone cells. Gene expression of cbfa-1, ALP, a1 chain of type I collagen, and osteocalcin were
upregulated in fetal bone cells after 12 days of treatment, with higher inductions than for adult and mesenchymal stem cells. The increase of
ALP enzymatic activity was stronger for fetal than for adult bone cells reaching a maximum at day 10, but lower than for mesenchymal stem
cells. Importantly, the mineralization process of bone fetal cells started earlier than adult bone and mesenchymal stem cells. Proliferation of
fetal and adult bone cells was increased by dexamethasone, whereas 1a,25-dihydroxyvitamin D3 did not show any proliferative effect.
Mineralization studies clearly demonstrated the presence of calcium deposits in the extracellular matrix of fetal bone cells. Nodule formation
and calcification were strongly increased by the differentiation treatment, especially by dexamethasone. This study shows for the first time
that human primary fetal bone cells could be of great interest for bone research, due to their fast growth rate and their ability to differentiate
into mature osteoblasts. They represent an interesting and promising potential for therapeutic use in bone tissue engineering.
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grafts by choosing the tissue engineering approach [1,2].
This strategy consists of three necessary elements: (1)
cells with a high osteogenic potential, easy to obtain and to
handle under standardized conditions, (2) osteogenic growth
factors, and (3) a synthetic three-dimensional scaffold which
gives the construct sufficient mechanical properties for
loading and facilitates vascularization.
The cell origin and type are essential aspects in bone
tissue engineering. This has been recapitulated by different
articles, particularly in the field concerning bone marrow-1323–1333
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cells derived from bone marrow is a stem cell, a procedure
of isolation is required to decrease the volume of material
injected [6]. Recently, a highly purified population of
stromal stem cells derived from human bone marrow was
described [7]. Exposure to growth factors or the combina-
tion with fibrillar collagen increased the proliferation of
stem cells and their differentiation into osteoblastic cells
[8,9]. However, the number of human mesenchymal stem
cells with osteogenic potential was shown to decrease early
during aging [10], and the proliferation of human bone
marrow stromal cells was reported to be negatively
correlated with the age of the donor in vitro [11].
Periosteal cells have been widely used in bone tissue
engineering by isolating osteoprogenitor cells from the
patient’s periosteum and seeding them into bioresorbable
scaffolds [12–16].
Fetal-associated tissues such as placenta, amniotic liquid,
or umbilical cord are described to be potential source of
cells for tissue engineering [17–20]. In contrast to embry-
onic derived up to the end of the eighth week, beginning at
the ninth week, cells are considered as fetal and tissue
dissection as organ donation. Human fetal liver cells have
been already used for transplantation to treat severe
immunodeficiencies, hematological disorders, and inborn
errors of metabolism, when there was no perfectly matched
donor for marrow transplantation [21]. Neuronal affections
such as Huntington [22] or Parkinson disease [23] have
been treated by transplantation of fresh fetal neuroblasts.
Unfortunately, these cells are difficult to expand in culture
and have to be transplanted freshly therefore needing large
quantities of fresh tissue [24]. Recently, human fetal skin
cells derived from one cell bank (1–4 cm2 tissue results in
over 10.5 million fetal skin constructs) were used in clinical
trials, and new advances in tissue therapy are possible with
cellular constructs obtained from ex vivo cultures (Hohlfeld,
J. submitted). Engineered regeneration of human skeletal
adult tissues could be also developed using human fetal
bone cells. To evaluate their potential integration in a bone
engineering strategy, a biological characterization of these
cells is necessary. To our knowledge, there is no available
description of human primary fetal bone cells behavior
when treated with factors of differentiation.
Age-dependent biology of osteoblasts is generally
accepted [25]. The particular biology of human primary
fetal bone cells was partially demonstrated with cells
isolated from calvaria [26]. They were found to secrete
primarily matrix constituents proteins in culture, whereas
adult cells produce additionally proteins involved in matrix
turnover. Age-dependent differences regarding the osteo-
blastic synthesis of osteoanabolic peptides and their impact
on the regeneration of osseous defects were observed with a
rat calvaria model [27].
Osteoblast development follows three main phases:
proliferation, matrix synthesis, and mineralization [28].
Factors for differentiation of osteoblasts are well de-scribed [29,30] and include ascorbic acid, h-glycerophos-
phate, 1a,25-dihydroxyvitamin D3 (1a,25-(OH)2D3), and
dexamethasone.
The aim of this work was to study the characteristics of
human primary fetal bone cells for a better comprehension
of their biology in vitro and to evaluate their potential use
for tissue engineering in comparison to adult bone cells and
mesenchymal stem cells. In the first part of this paper, fetal
bone cells, adult bone cells, and mesenchymal stem cells are
compared for their self-renewal capacity and their osteo-
genic induction when treated with differentiation mix. Their
osteoblastic phenotype is presented at the gene expression
level, such as the core binding factor alpha 1 (cbfa-1), a
critical transcription factor for osteoblast differentiation and
function [31–33]; alkaline phosphatase (ALP) [34]; a1
chain of type I collagen, which represents 85–90% of the
total organic bone matrix [35]; and osteocalcin, which
constitutes 1–2% of the total protein of bone [36]. At the
protein level, ALP enzymatic activity and the ability of
matrix mineralization are observed. In the second part of
this paper, the effects of different osteoinductor factors on
human primary fetal bone cells are examined to further
characterize their ability to differentiate.Materials and methods
Cell sources
Human fetal and adult bone cells were obtained from our
bank of bone cells comprising 32 adult donors (18 females
and 14 males) and 4 fetal donors (1 female and 3 males) at
the end of March 2004. More than 250 primary total hip
replacements with potentially interesting orthopedic tissue
samples were performed during the year 2002 at the Hoˆpital
Orthope´dique de la Suisse Romande. Documents relative to
the patients were consulted to assure no major disease,
medications, or alcohol consumption. Bone samples were
extensively collected, and care was taken to obtain healthy
bone samples. In particular, the selected adult bone cells are
coming from donors without bone necrosis. In this study,
human trabecular bone biopsies at femoral locations
obtained from 31-, 50-, and 60-year-old adult women
subsequent to orthopedic surgery and from fetus of 13,
14, and 16 weeks’ gestational age following voluntary
interruption of pregnancy were used. Biopsies were ob-
tained in accordance with the Ethics Committee of
University Hospital in Lausanne (Ethical Protocol 51/01).
Primary osteoblast cultures were established by rinsing the
tissue first with PBS (containing penicillin and streptomy-
cin). Afterwards, bone samples were mechanically disso-
ciated with a scalpel blade and transferred to 10-cm culture
grade plates where cell outgrowth was seen within 2 to 5
days under normal culture conditions : DMEM Glutamax
(Invitrogen, Carlsbad, CA), 10% FCS (Sigma–Aldrich, St.
Louis, MO). Commercially available mesenchymal stem
Table 1
Comparison of the doubling time of human fetal bone, adult bone, and
mesenchymal stem cells
A. Fetal bone cells
Donor Age (weeks) Passage 3 (h) Passage 6 (h)
1 16 27.0 (F0.2) 30.2 (F1.5)
2 14 22.6 (F0.5) 25.1 (F0.7)
3 13 30.3 (F0.1) 31.4 (F0.1)
B. Adult bone cells
Donor Age (years) Passage 3 (h)
1 60 248.7 (F20.1)
2 50 170.5 (F11.8)
3 31 151.6 (F5.6)
C. Mesenchymal stem cells
Donor Age (years) Passage 3 (h)
1 26 26.5 (F0.9)
Experiments were performed in triplicates and presented as mean values
(FSEM).
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from the posterior iliac crest of the pelvic bone from young
and healthy volunteers, were tested parallelly.
Cell culture
Fetal and adult bone cells were maintained in culture by
passaging once a week and culturing at 378C in an
humidified, 5% CO2 atmosphere in DMEM Glutamax,
10% FCS. Mesenchymal stem cells were expanded in
MSCGM growth medium (Cambrex Bio Science). Culture
media were changed twice a week.
For the comparison between fetal bone cells, adult bone
cells, and mesenchymal stem cells, 1a,25-(OH)2D3 10 nM
(Alexis Biochemicals, San Diego, CA), dexamethasone 10
nM (Sigma–Aldrich), additionally to l-ascorbic acid 50 Ag/
ml (Sigma–Aldrich), and h-glycerophosphate 1 mM
(Sigma–Aldrich) were added in their respective growth
medium to obtain the full differentiation mix. For the
characterization of fetal bone cells, osteogenic factors were
tested as follows: ascorbic acid 50 Ag/ml and h-glycer-
ophosphate 1 mM (minimal differentiation mix); ascorbic
acid 50 Ag/ml, h-glycerophosphate 1 mM, and dexametha-
sone 10 nM (dexamethasone mix); ascorbic acid 50 Ag/ml,
h-glycerophosphate 1 mM, and 1a,25-(OH)2D3 10 nM
(vitamin D3 mix); and ascorbic acid 50 Ag/ml, h-glycer-
ophosphate 1 mM, dexamethasone 10 nM, and 1a,25-
(OH)2D3 10 nM (full differentiation mix). In general,
passage 3 was used for all experiments. Concerning fetal
bone cells, the same assays were performed at passage 6 to
verify their multilineage capability. Each procedure was
repeated three times, starting from a new vial of cells which
were stored in liquid N2. Unless otherwise stated, results
presented were obtained with the 16-week-old donor for the
fetal source and the 50-year-old donor for the adult bone
cells (Table 1). Similar data were obtained with two other
fetal and adult donors.
Cell proliferation
To determine their doubling time, cells were seeded at a
density of 440,000 cells/T75 flask. Every day, up to 10 days,
triplicates were washed twice with PBS, and cells were
detached using trypsin–EDTA (Invitrogen). Subsequently,
the cell number was determined in a counting chamber
(Marienfeld GmbH & Co. KG, Lauda-Koenigshofen,
Germany). The growth constant and the generation time
were determined during the exponential cell growth [37].
To evaluate the effects of osteogenic factors on prolif-
eration, cells were seeded at 5000 cells/well in 96-well
plates and incubated for 24 h at 378C in a humidified, 5%
CO2 atmosphere in normal culture medium. The medium
was then replaced by 100 Al/well fresh medium containing
the factors of differentiation. Every second day, up to 12
days, a plate was analyzed for cell proliferation, and the
medium of the remaining plates was renewed. Measure-ments were performed in triplicate for each time point. The
relative number of viable cells in each well was determined
with the CellTiter 96R AQueous One Solution Cell
Proliferation Assay (Promega, Madison, WI) according to
the manufacturer’s instructions. This colorimetric method is
based on the bioreduction of the MTS tetrazolium com-
pound into a colored formazan product which is soluble in
culture medium. It was determined to produce a linear
relationship between the number of viable cells and the
absorbance at 490 nm.
Briefly, 20 Al of the reagent solution was added to each
well, including three wells containing only medium for
background subtraction. After incubation for 90 min at
378C, the absorbance was recorded at 490 nm using a
Wallac 1420 VICTOR2 multilabel plate reader (Wallac Oy,
Turku, Finland).
RNA isolation and purification
Cells were seeded in 6-cm Petri dishes at a density of
300,000 cells/dish. Treatment began 24 h later, with culture
media changed every second day. At the same time points,
samples were removed for gene expression analysis. RNA
isolation and purification procedures were performed using
NucleospinR RNA II columns (Macherey-Nagel, Dqren,
Germany) with the furnished protocol. RNA was eluted in
40 Al of RNase-free water and stored at 808C until
required.
First strand synthesis
For each sample, 5 Al of total RNA was reverse-
transcribed using the Taqman Universal polymerase chain
reaction (PCR) reagents with random hexamers (Applied
Biosystems, Foster City, CA). Reaction volumes were fixed
Fig. 1. (A) Proliferation curves of fetal bone cells (n), adult bone cells (o),
and mesenchymal stem cells (4). Cells were treated with ascorbic acid
50 Ag/ml, h-glycerophosphate 1 mM, dexamethasone 10 nM, and 1a,25-
(OH)2D3 10 nM (full differentiation mix). (B) Proliferation of fetal bone
treated with ascorbic acid 50 Ag/ml and h-glycerophosphate 1 mM
(minimal differentiation mix, 5); ascorbic acid 50 Ag/ml, h-glycerophos-
phate 1 mM and dexamethasone 10 nM (dexamethasone mix, !); ascorbic
acid 50 Ag/ml, h-glycerophosphate 1 mM, and 1a,25-(OH)2D3 10 nM
(vitamin D3 mix, 4); ascorbic acid 50 Ag/ml, h-glycerophosphate 1 mM,
dexamethasone 10 nM, and 1a,25-(OH)2D3 10 nM (full differentiation mix,
n). Optical densities are expressed as ratios relative to day 0 levels. Results
are shown as the meanF SEM of three experiments performed in triplicate.
Media were renewed every second day.
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The thermal cycler PCT-0100 (MJ Research, Waltham, MA)
was programmed as follows: 258C 10 min, 488C 30 min,
and 958C 5 min.
Real time polymerase chain reaction
Specific primers for cbfa-1, a1 chain of type I collagen,
osteocalcin, ALP, and for the housekeeping 18S RNA were
designed with the Primer ExpressR software (Applied
Biosystems) and purchased from Integrated DNA Technol-
ogies (Coralville, IA). An additional sequence of 18 bp was
added to the 5’ end of every forward primer to use the
AmplifluorR UniprimerR technology (Intergen Discovery
Products, Purchase, NY). PCR reactions were performed in
25 Al: 5 Al of first strand, 12.5 Al of TaqMan Universal PCR
Master Mix (Applied Biosystems), and 7.5 Al of the primers
working solution. Thermal cycle conditions were 508C 2
min, 958C 10 min, then 50 cycles at 958C 15 s, 608C 1 min.
Amplifications were monitored with the ABI Prism 7700
(Applied Biosystems). Measurements were performed in
duplicates for each time point. Relative gene expressions
were analyzed with the 2-DDCT method [38]. Normalized to
18S RNA, each gene expression was compared with the
DCT calibrator value from the untreated group. PCR
products were purified using WizardR SV gel and PCR
Clean-Up system (Promega) and sequenced with the ABI
Prism 3100 Genetic Analyser, using the Big Dye Terminator
v3.1 Cycle Sequencing Kit Chemistry (Applied Biosys-
tems). Results were in accordance with the expected
sequences (data not shown).
Alkaline phosphatase activity
Cells were seeded at 5000 cells/well in 96-well plates and
incubated for 24 h at 378C in a humidified, 5% CO2
atmosphere in normal culture medium. The medium was
then replaced with 100 Al/well fresh medium containing the
osteogenic factors. Every second day, up to 12 days, a plate
was analyzed for the alkaline phosphatase activity, and the
medium in the remaining plates was renewed at this
occasion. Measurements were performed in triplicates for
each time point. Alkaline phosphatase activity was deter-
mined using p-nitrophenol tablets as substrate (Sigma–
Aldrich). The ALP activity values were normalized to the
total protein content determined using the total cellular
protein assay (see below). Calculations were done according
to the manufacturer’s instructions (Sigma, procedure n8245).
Total cellular protein
Cells were seeded at the same density as for the alkaline
phosphatase activity assay, and same treatments were
applied. At each time point, cells were rinsed twice with
PBS, and the total protein was determined in cell lysates
using the Bio-Rad protein assay (Bio-Rad Laboratories,Hercules, CA). Measurements were performed in triplicates
for each time point. Total protein values were quantified
using a standard curve obtained with a serial dilutions of
bovine serum albumin contained in the Bio-Rad Protein
Assay Standard II (Bio-Rad Laboratories).
In vitro mineralization
Cells were seeded at 5000 cells/well in 96-well plates and
incubated for 24 h at 378C in a humidified, 5% CO2
atmosphere in normal culture medium. The medium was
then replaced by the differentiation factors. The experiment
was performed twice, with 5 wells for each condition. The
mediumwas renewed every second day. Up to 6 weeks, every
week, a plate was analyzed for mineralization. MC3T3 E1
cells were used as positive control. The degree of in vitro
calcium deposition was determined using Von Kossa stain-
ing. Briefly, the mediumwas removed from the wells, and the
cells were rinsed three times with PBS. After washing, the
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formalin was removed, and the cells were washed three times
with deionized water. The cells were then stained with
AgNO3 solution 5% (in water). The plates were exposed for 1
h under UV light and washed three times with water. The
water was removed, and a solution of sodium-thiosulfate 5%
(in water) was added for 2 min. Finally, cells were washed
three times with water, and samples were examined for black
clusters by light microscopy.
Scanning electron microscopy
Fetal bone cells were seeded at 100,000 cells/well in 6-
well plates and treated during 6 weeks under the same
conditions as described for the mineralization assay.
Subsequently, cells were fixed with glutaraldehyde, fol-
lowed by a dehydration procedure in ethanol. The sample
surfaces were gold-coated during 2 min under 1 kV and
observed using a scanning electron microscope Philips
XL30 (FEI, Hillsboro, OR) at a voltage of 5 kV.
Statistical analyses
Data were analyzed using the two-way ANOVA to
determine the difference between cells behaviors (XLSTAT,
Addinsoft, Brooklyn, NY). The Fisher LSD test was used toFig. 2. Gene expression of cbfa-1 (A), a1 chain of type I collagen (B), alkaline ph
ascorbic acid 50 Ag/ml, h-glycerophosphate 1 mM, dexamethasone 10 nM, and 1
second day. The expression of fetal bone cells (n), adult bone cells (o), and m
respective untreated group. Results are plotted as the mean F SEM of three indidetermine statistical significance between sample sets. A
value of P b 0.05 was taken as a significant difference. The
same approach was used to evaluate the effects of differ-
entiation factors on bone fetal cells. Results are shown as the
mean F SEM. Comparisons of proliferation and ALP
enzymatic activity between cells are expressed as ratios of
respective inductions. Effects of the different osteogenic
treatments on bone fetal cells are expressed as percent (%)
change versus the reference.Results
Cell proliferation
Growth curves obtained for human primary fetal and
adult bone cells show that the former proliferated consid-
erably more rapidly than mature cells which displayed a
much slower and clearly age-dependent doubling time. For
fetal bone cells, it was determined by cell counting to vary
between 23 and 27 h, depending on the donor (Table 1). A
similar value was obtained with mesenchymal stem cells.
For adult bone cells derived from a 31- and 50-year-old
donor, it was determined to be 152 and 170 h, respectively,
while cells coming from a 60-year-old donor showed a
doubling time even as slow as 249 h.osphatase (C), and osteocalcin (D) quantified by RT–PCR after exposure to
a,25-(OH)2D3 10 nM (full differentiation mix). Media were renewed every
esenchymal stem cells (4) are shown as 2-DDCT values, relative to their
vidual experiments.
Fig. 3. (A) ALP enzymatic activity of fetal bone cells (n), adult bone cells
(o), and mesenchymal stem cells (4). Cells were treated with ascorbic acid
50 Ag/ml, h-glycerophosphate 1 mM, dexamethasone 10 nM, and 1a,25-
(OH)2D3 10 nM (full differentiation mix). (B) ALP enzymatic activity of
fetal bone cells treated with ascorbic acid 50 Ag/ml and h-glycerophosphate
1 mM (minimal differentiation mix, 5); ascorbic acid 50 Ag/ml, h-
glycerophosphate 1 mM, and dexamethasone 10 nM (dexamethasone mix,
!); ascorbic acid 50 Ag/ml, h-glycerophosphate 1 mM, and 1a,25-
(OH)2D3 10 nM (vitamin D3 mix, 4); ascorbic acid 50 Ag/ml, h-
glycerophosphate 1 mM, dexamethasone 10 nM, and 1a,25-(OH)2D3 10
nM (full differentiation mix, n). Ratios relative to the untreated group at
day 0 are shown. Results are expressed as the mean F SEM of three
experiments performed in triplicate. Media were renewed every second day.
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entiation mix was significantly higher for the fetal bone
cells than for the adult bone cells starting from day (d) 6
until the end of the experiment (Fig. 1A). Maximum
difference was observed at day 12 (252.3% of the induction
of adult bone cells, P b 0.01). For this parameter, there was
no significant difference between the mesenchymal stem
cells and the fetal bone cells treated with osteogenic
factors.
Dexamethasone had a positive effect on proliferation of
fetal bone cells (Fig. 1B). Compared to the minimal
differentiation mix, it was significatively higher starting at
day 8. This difference was observed with the same range
until the end of the experiment (d8: +47%, P b 0.05; d10:
+69%, P b 0.0091; d12: +68%, P b 0.0022). Conversely,
the vitamin D3 mix did not have a proliferative effect. When
added together with dexamethasone, 1a,25-(OH)2D3
reduced the growth rate significantly at day 12, compared
to dexamethasone alone (24%, P b 0.033).
Gene expression
Results of relative gene expression obtained by real-time
RT–PCR for cbfa-1, a1 chain of type I collagen, ALP, and
osteocalcin are shown in Fig. 2 for human primary fetal bone
cells in comparison with adult bone cells and mesenchymal
stem cells. Cbfa-1 gene expression (Fig. 2A) of fetal bone
cells started to increase at day 6 and reached a maximum at
day 12 with a 3-fold higher upregulation than observed for
the adult bone cells (315.9%; P = 0.001) and a 56-fold higher
upregulation than obtained for the mesenchymal stem cells
(5586.5%; P = 0.002) at this time point. Strongest
upregulation of the a1 chain of type I collagen gene (Fig.
2B) was also observed for the fetal bone cells. At day 12,
fetal bone cells showed a significantly higher level of gene
expression than adult bone cells (279.5%; P = 0.0112) and
mesenchymal stem cells (1108.7%; P = 0.0022). For the fetal
bone cells, upregulation of the ALP gene (Fig. 2C) started at
day 6 and increased continuously until day 12. At this time
point, strongest differences in gene expression were
observed with a 9-fold higher upregulation compared to
adult bone cells (875%; P = 0.0011) and an even 140-fold
higher expression than obtained for mesenchymal stem cells
(13,635%; P = 0.0006). Osteocalcin gene expression (Fig.
2D) of fetal bone cells was induced slowly and late, with a
significantly higher upregulation of the gene in fetal bone
cells than in adult bone cells (201.2; P = 0.0126) and in
mesenchymal stem cells (372.9%; P = 0.0022) at the end of
the experiment.
Alkaline phosphatase activity
The induction of ALP enzymatic activity with the full
differentiation mix was significantly higher for the mesen-
chymal stems cells than for the fetal and the adult bone cells
starting from day 4 until the end of the experiment (Fig.3A). Maximum difference was observed at day 6 (255.9%
of the induction of fetal bone cells, P b 0.001, and 487.6%
of adult bone cells induction, P b 0.0003). Compared with
adult bone cells, fetal bone cells showed a higher induction
of ALP enzymatic activity with a maximum difference at
day 10 (222.2%, P b 0.0007). Detailed effects on ALP
activity of 1a,25-(OH)2D3 and dexamethasone when added
to ascorbic acid and h-glycerophosphate for fetal bone cells
are shown in Fig. 3B. ALP enzymatic activity was enhanced
in the group treated with the full differentiation mix, with a
first significant difference comparing with the DMEM
group at day 4 (d4: +322%, P b 0.0179; d6: +84%, P b
0.0054; d8: +530%, P b 0.002; d10: +183%, P b 0.0001;
d12: +283%, P b 0.0002). The dexamethasone mix had also
an increasing effect but starting at day 6 (d6: +81%, P b
0.0067; d8: +541%, P b 0019; d10: +246%, P b 0.0001;
d12: +188% P b 0.0042). A comparable pattern was
observed with adult bone cells, but the inductions were
reduced comparatively to fetal bone cells (data not shown).
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First positive Von Kossa staining of fetal bone cells was
obtained after 2 weeks of treatment with the full differ-
entiation mix (Fig. 4A), as for MC3T3 E1 used as positive
control (data not shown). In contrast, adult bone cells and
mesenchymal stem cells did not show positive Von Kossa
staining after 2 weeks of treatment, but after 5 and 3 weeks
of treatment, respectively (data not shown). The same
patterns as for the fetal cells were then obtained treating
these cells for a longer period (data not shown). Further
studies on fetal bone cells showed that dexamethasone did
strongly increase in vitro calcium deposition, whereas
1a,25-(OH)2D3 did not show a comparable effect (Fig.
4B). Nodule formation was visible after the first week and
strongly enhanced starting from the second week of treat-
ment for fetal cells receiving the full differentiation mix
(Fig. 5A), whereas no obvious difference was observed forFig. 5. (A) Bone-like nodule formation observed with fetal bone cells after 2
weeks. Control group and group treated with ascorbic acid 50 Ag/ml, h-
glycerophosphate 1 mM, dexamethasone 10 nM, and 1a,25-(OH)2D3 10 nM
(full differentiation mix) are shown. First nodules were detected in the
control group after the first week, and their number was increasing with time.
(B) Extracellular matrix of fetal bone cells after 4 weeks of treatment with
ascorbic acid 50 Ag/ml, h-glycerophosphate 1 mM, dexamethasone 10 nM,
and 1a,25-(OH)2D3 10 nM (full differentiation mix). SEM micrograph and
SEM energy dispersive x-rays spectroscopy analysis are presented. Arrows
indicate characteristic peaks of energy corresponding to Ca and P elements.
Media were renewed every second day.
Fig. 4. (A) Von Kossa staining of the extracellular matrix of fetal bone cells,
adult bone cells, and mesenchymal stem cells after 2 weeks of treatment.
Control () and treated (+) groups are shown. Cells treated received
ascorbic acid 50 Ag/ml, h-glycerophosphate 1 mM, dexamethasone 10 nM,
and 1a,25-(OH)2D3 10 nM (full differentiation mix). Media were renewed
every second day. First positive stainings were observed after 3 and 5 weeks
for mesenchymal cells and adult bone cells, respectively. At these time
points, the groups treated with the full differentiation mix were markedly
Von Kossa positive. (B) Von Kossa staining of fetal bone cells treated with
ascorbic acid 50 Ag/ml and h-glycerophosphate 1 mM (minimal differ-
entiation mix); ascorbic acid 50 Ag/ml, h-glycerophosphate 1 mM, and
dexamethasone 10 nM (dexamethasone mix); ascorbic acid 50 Ag/ml, h-
glycerophosphate 1 mM, and 1a,25-(OH)2D3 10 nM (vitamin D3 mix);
ascorbic acid 50 Ag/ml, h-glycerophosphate 1 mM, dexamethasone 10 nM,
and 1a,25-(OH)2D3 10 nM (full differentiation mix). Media were renewed
every second day.adult cells at this time point (data not shown). Interestingly,
fetal bone cells were able to constitute nodules even without
any treatment of differentiation. When observed by scan-
ning electron microscopy after 4 weeks of treatment, highly
organized structures containing layers of cells trapped in an
abundant collagenous matrix and aggregates were distin-
guishable in these nodules. Energy dispersive x-rays
spectroscopy analysis did clearly identify the characteristic
peaks of energy corresponding to Ca and P elements,
indicating that in vitro mineralization occurred (Fig. 5B).
Nodules were observed for adult cells starting from the fifth
week and calcium phosphate crystal deposits 1 week later
(data not shown).
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The aim of this work was to investigate the osteoblastic
potential of human primary fetal bone cells in vitro and to
evaluate their possible use for tissue engineering. We first
compared the behavior of bone fetal cells to adult bone and
mesenchymal stem cells for their responsiveness to osteo-
genic factors. Then we characterized fetal bone cells in more
details for their ability to be induced into the bone pathway.
A key finding was the observation of spontaneous bone-like
nodule formation after only 2 weeks and before adult cells
and mesenchymal stem cells. Additionally, fetal bone cells
showed a strong response to differentiation factors.
The growth rate of fetal bone cells was similar to
mesenchymal stem cells, but faster than the growth rate of
bone cells from a 31-year-old donor. The proliferative
ability was even slower with cells obtained from older
donors (Table 1). This age dependency was already
observed and could be attributed to a decrease of
proliferative precursor cells on trabecular bone surfaces
[39]. However, age-dependent changes in the population of
osteoprogenitor cells are discussed controversially. Recent
results have given evidence of aging in marrow stromal
progenitor cells [10,40–46]. Other reports demonstrated that
osteogenic progenitor cells were maintained during aging
[47–49]. The question of changes in the osteoprogenitor cell
population with age is further complicated by the possibility
of sex-dependent differences [50–52]. Age-related osteopo-
nia may also depend from the skeletal site, depending to the
variable trabecular–cortical bone ratio at different locations
[53]. The proliferative aptitude is of major interest in the
perspective to use human primary fetal bone cells for
research or tissue engineering: a rapid expansion facilitates
the creation of an important bank of cells, starting from one
donor. Remarkably, the high capacity for self-renewal in
vitro did correlate with telomerase activity for fetal cells, as
demonstrated by the telomerase repeat amplification proto-
col assay (data not shown). In addition to its role in cell
replication, telomerase is required for differentiation of
murine bone marrow mesenchymal stem cells in vitro [54].
A possible mechanism leading to in vitro accelerated
osteogenesis by telomerized bone marrow stromal stem
cells could be attributed to the upregulation of the
osteogenic genes cbfa-1, osteorix and osteocalcin [7]. The
presence of ascorbic acid and h-glycerophosphate had no
effect on proliferation. This observation was previously
described for rat calvaria osteoblasts in cultures which
maintained the same growth rate when h-glycerophosphate
was added to ascorbic acid [28]. Dexamethasone accelerated
the proliferation of both fetal and adult bone cells. When
treated with dexamethasone or basic fibroblast growth
factor, adult cells were proliferating faster but significantly
slower than fetal cells from the untreated DMEM group
(data not shown). Although 1a,25-(OH)2D3 did not have
any effect on proliferation compared with the minimal
differentiation mix, its presence slowed down the positiveeffect of dexamethasone. This was detected with fetal as
well as with adult cells. The combining action of the two
hormones was described to strongly increase the adipocyte
population and their differentiation but to decrease the
osteoblastic cell population in a long-term rat bone marrow
culture [55]. Osteoblastic cell proliferation and differentia-
tion were increased by dexamethasone and inhibited by
1a,25-(OH)2D3. Our findings are in accordance with these
observations, and further studies are needed to address the
issues concerning adipocyte differentiation.
During this proliferative sequence, genes involved in the
production and deposition of extracellular matrix started to
be expressed which denotes a strong osteogenic potential of
primary fetal bone cells compared to adult and mesenchy-
mal stem cells. The induction of cbfa-1 gene expression
observed is essential for osteoblast function and differ-
entiation. It is also a critical gene involved in bone matrix
deposition [56]. Early upregulation of collagen Ia1 con-
firmed its induction before any other current matrix
component and prior to ALP [28,57,58]. Fetal cell gene
expression of ALP was augmented due to the presence of
dexamethasone, 1a,25-(OH)2D3, ascorbic acid, and h-
glycerophosphate. The time course of ALP gene expression
roughly fits with the increase of activity of this enzyme.
These results are consistent with previous studies where the
regulation of ALP by glucocorticoids was ascertained at
protein and mRNA levels [59–61]. Exposing the rat
osteosarcoma cell line ROS 17/2.8 to dexamethasone, the
rise in alkaline phosphatase mRNA levels could be
attributed entirely to an increase in gene transcription [62].
The immortalized human fetal osteoblastic cell line hFOB/
ER9 showed an increase of ALP activity during mineraliza-
tion [63], whereas in rat fetal calvaria cultures, ALP was
expressed maximally during the early stages of differ-
entiation [28]. In our model, ALP activity of fetal bone cells
reached a maximum activity after 10 days, when nodule
formation started to be markedly enhanced. ALP enzymatic
activity of mesenchymal stem cells was also strongly
enhanced by osteogenic factors. Adult bone cells showed
the same pattern for ALP enzymatic activity, with an earlier
induction for the full differentiation mix, compared with the
group receiving only dexamethasone additionally to ascor-
bic acid and h-glycerophosphate (data not shown). For adult
cells, ALP enzymatic activity was observed to vary
according to the age of the donor as previously demon-
strated [64].
Osteocalcin, one of the most abundant noncollagenous
proteins in bone, was also upregulated at the gene
expression level, first in adult bone cells, and later in fetal
bone cells. This was not observed with mesenchymal stem
cells during the first 12 days of treatment, indicating that
their extracellular matrix maturation was not as advanced as
fetal cells. The delayed mineralization observed with
mesenchymal stem cells in comparison with fetal cells
could be due to their less differentiated phenotype.
Corroborating this observation, osteocalcin gene expression
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did not upregulate their cbfa-1 expression during the
treatment. Although its biological function has not been
precisely defined, specific interaction with hydroxyapatite
was demonstrated [65]. New evidence indicates that
osteocalcin participates in the regulation of mineralization
and bone turnover [28]. A vitamin D regulatory element was
identified in its promoter [66–69]. In most species, 1a,25-
(OH)2D3 upregulates osteocalcin biosynthesis. Upregulation
of osteocalcin indicated that fetal bone cells were fully
differentiated into osteoblasts and started to mineralize. This
was in accordance with the fact that in vitro calcium
deposition was observed by Von Kossa staining after 2
weeks of treatment. Nodule formation increased gradually
and was maximum at the end of the treatment (data not
shown). Dexamethasone augmented the nodule number
dramatically, when added to ascorbic acid and h-glycer-
ophosphate. Comparable results were obtained with murine
embryonic stem cells [70]. In primary rat calvaria cell
cultures, additional nodule formation was observed, and the
self-renewal capacity of the bone-nodule forming cells was
increased [71]. This could be due to the induction of
proliferation of more mature osteoblast precursors, enabling
them to achieve sufficient numbers of cell divisions to form
a visible nodule, or the effect targeted a separate sub-
population of progenitors requiring glucocorticoid to pro-
liferate and/or differentiate [10,72]. The existence of
subpopulations of osteoblasts that differs in their respon-
siveness to dexamethasone was previously suggested in
clonal rat osteosarcoma cells [73].
Furthermore, characterization of the mineralized bone
nodules by scanning electron microscopy clearly demon-
strated that they were made of osteoblasts, extracellular
collagen fibrils, and crystal deposits. Detailed analysis of the
crystals by energy dispersive x-rays spectroscopy showed
that these structures were containing Ca and P elements.
Such a substratum produced by differentiating osteoblasts
was described as an anchorage for calcifying collagen fibers
synthesized by the same cells in a rat model [74]. Signs of
mineralization are fundamental in perspective to use
primary fetal bone cells for artificial bone synthesis.
For this study, the number of passages was arbitrarily
fixed to 3. Similar results concerning fetal bone cells
proliferation rate, ALP activity, and in vitro mineralization
were obtained at passage 6 (data not shown), demonstrating
that the multilineage capability was maintained.
In conclusion, our data support the idea that human
primary fetal bone cells are able to differentiate into mature
osteoblasts when stimulated. This full differentiation proc-
ess displayed the appearance of specifically mineralized
bone-like nodules. Due to their more rapid growing rate and
their strong responsiveness to differentiation treatment
compared with adult cells and mesenchymal stem cells,
their use could be of great interest for fundamental research,
pharmaceutical screenings, and especially for bone tissue
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